|
|
 |
Investment Funds
Finistere Ventures has two active Funds: FINISTERE – CHICAGO
PARTNERS I and
FINISTERE – OCEANIA PARTNERS I.
The Finistere Ventures active Funds are closed and have been in an active investment phase since their inception in 2005. These Funds are continuing to be invested and plan to remain in their active phase through 2010. Our approach is to co-invest our existing pools of funding in opportunities that fit with our investment strategy.
Our investment strategy is outlined on our Investment Strategy section.
A new fund raising is planned and further details will be announced in 2007. Potential investors with an interest in becoming a Limited Partner and/or Strategic Investor may direct their enquiries to info@finistereventures.com
The funds operated by Finistere Partners LLC can be viewed at www.finisterepartners.com
At Finistere Ventures, we focus on early stage investments and are typically involved in the initial professional financing of start-up companies in the Agbio & Medical Device industries. We believe that these asset classes are where our team and networks offer our investors the greatest opportunity for superior returns.
In principle, we do not invest in Public Companies, or in mature project financing opportunities that are better served by the Private Equity industry.
The technologies and market segments that we focus on in the life sciences industry are characterized by high growth with strong market drivers from both developed and emerging markets.
Finistere Ventures operates principally in the US market, but will invest in sourcing technologies from outside the US where there is an opportunity to migrate and develop the company towards an exit in the US market. In addition, our colleagues at Finistere Partners focus on sourcing investment opportunities from Australia and New Zealand where there are excellent sources of science and which can be migrated to the US market for development, commercialization and exit. Where there are synergies we will seek to co-invest with our sister Funds in these businesses, giving us additional sources of dealflow.
From an investment standpoint, we see the agbio, industrial biotech and medical devices markets involving less risk than other segments of Life Sciences such as the human therapeutics industry. Both agbio and medical devices have relatively shorter product development time lines, fewer regulatory hurdles and lower capital costs. However, they are consolidated industries with large players that invest significantly to acquire new technologies from smaller start-ups. Currently, both the agbio and medical devices industries are in an investment upswing that will last well in to the next decade, offering fertile ground for new venture investment.
Ultimately, we are looking to provide exits and returns for our investors within five years of an investment, which we believe is in alignment with the opportunities available in our targeted sectors, and is appropriate to the venture investment model returns we expect for our Investors.
